Skip header and navigation

Refine By

1 records – page 1 of 1.

Transparency in drug regulation: mirage or oasis?

https://arctichealth.org/en/permalink/ahliterature177289
Source
CMAJ. 2004 Nov 23;171(11):1363-5
Publication Type
Article
Date
Nov-23-2004
Author
Joel Lexchin
Barbara Mintzes
Author Affiliation
Emergency Department, University Health Network, School of Health Policy and Management, York University, Toronto, Ont. joel.lexchin@utoronto.ca
Source
CMAJ. 2004 Nov 23;171(11):1363-5
Date
Nov-23-2004
Language
English
Publication Type
Article
Keywords
Access to Information - legislation & jurisprudence
Antidepressive Agents - therapeutic use
Bias (epidemiology)
Canada
Cardiovascular Diseases - chemically induced
Clinical Trials as Topic - standards
Cyclooxygenase Inhibitors - adverse effects
Drug Approval - organization & administration
Drug Industry - legislation & jurisprudence
Hormone Replacement Therapy - adverse effects
Humans
Publishing - standards
Pyrazoles
Sulfonamides - adverse effects
Notes
Cites: JAMA. 2001 Nov 21;286(19):2398-40011712925
Cites: Lancet. 2000 Feb 12;355(9203):566-910683020
Cites: JAMA. 2000 Sep 13;284(10):1247-5510979111
Cites: JAMA. 2001 Nov 21;286(19):2398; author reply 2399-40011712924
Cites: BMJ. 1997 Jul 19;315(7101):149-539251544
Cites: JAMA. 2002 Jul 17;288(3):321-3312117397
Cites: BMJ. 2003 May 31;326(7400):1171-312775615
Cites: BMJ. 2004 Feb 28;328(7438):518-2014988197
Comment In: CMAJ. 2005 Jun 21;172(13):1664; author reply 1664-515967953
PubMed ID
15557590 View in PubMed
Less detail